Genome wide analysis of circulating miRNAs in growth hormone secreting pituitary neuroendocrine tumor patients' plasma.
acromegaly
circulating plasma micro-RNAs
growth hormone secreting pituitary neuroendocrine tumor
micro-RNA differential expression
somatostatin analogue treatment
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2022
2022
Historique:
received:
11
03
2022
accepted:
15
08
2022
entrez:
26
9
2022
pubmed:
27
9
2022
medline:
27
9
2022
Statut:
epublish
Résumé
Circulating plasma miRNAs have been increasingly studied in the field of pituitary neuroendocrine tumor (PitNET) research. Our aim was to discover circulating plasma miRNAs species associated with growth hormone (GH) secreting PitNETs versus assess how the plasma levels of discovered miRNA candidates are impacted by SSA therapy and whether there is a difference in their levels between GH secreting PitNETs versus other PitNET types and healthy individuals. We compared plasma miRNA content and levels before and after surgery focusing on GH secreting PitNET patients. Selected miRNA candidates from our data and literature were then tested in a longitudinal manner in somatostatin analogues (SSA) treatment group. Additionally, we validated selected targets in an independent GH secreting PitNET group. miRNA candidates were discovered using the whole miRNA sequencing approach and differential expression analysis. Selected miRNAs were then analyzed using real-time polymerase chain reaction (qPCR). Whole miRNA sequencing discovered a total of 16 differentially expressed miRNAs (DEMs) in GH secreting PitNET patients' plasma 24 hours after surgery and 19 DEMs between GH secreting PitNET patients' plasma and non-functioning (NF) PitNET patients' plasma. Seven miRNAs were selected for further testing of which miR-625-5p, miR-503-5p miR-181a-2-3p and miR-130b-3p showed a significant downregulation in plasma after 1 month of SSA treatment. mir-625-5p was found to be significantly downregulated in plasma of GH secreting PitNET patients vs. NF PitNET patients. miR-625-5p alongside miR-130b-3p were also found to be downregulated in GH PitNETs compared to healthy individuals. Our study suggests that expression of plasma miRNAs miR-625-5p, miR-503-5p miR-181a-2-3p and miR-130b-3p in GH secreting PitNETs is affected by SSA treatment. Additionally, miR-625-5p can distinguish GH secreting PitNETs from other PitNET types and healthy controls warranting further research on these miRNAs for treatment efficacy.
Sections du résumé
Background
Circulating plasma miRNAs have been increasingly studied in the field of pituitary neuroendocrine tumor (PitNET) research. Our aim was to discover circulating plasma miRNAs species associated with growth hormone (GH) secreting PitNETs versus assess how the plasma levels of discovered miRNA candidates are impacted by SSA therapy and whether there is a difference in their levels between GH secreting PitNETs versus other PitNET types and healthy individuals.
Design
We compared plasma miRNA content and levels before and after surgery focusing on GH secreting PitNET patients. Selected miRNA candidates from our data and literature were then tested in a longitudinal manner in somatostatin analogues (SSA) treatment group. Additionally, we validated selected targets in an independent GH secreting PitNET group.
Methods
miRNA candidates were discovered using the whole miRNA sequencing approach and differential expression analysis. Selected miRNAs were then analyzed using real-time polymerase chain reaction (qPCR).
Results
Whole miRNA sequencing discovered a total of 16 differentially expressed miRNAs (DEMs) in GH secreting PitNET patients' plasma 24 hours after surgery and 19 DEMs between GH secreting PitNET patients' plasma and non-functioning (NF) PitNET patients' plasma. Seven miRNAs were selected for further testing of which miR-625-5p, miR-503-5p miR-181a-2-3p and miR-130b-3p showed a significant downregulation in plasma after 1 month of SSA treatment. mir-625-5p was found to be significantly downregulated in plasma of GH secreting PitNET patients vs. NF PitNET patients. miR-625-5p alongside miR-130b-3p were also found to be downregulated in GH PitNETs compared to healthy individuals.
Conclusions
Our study suggests that expression of plasma miRNAs miR-625-5p, miR-503-5p miR-181a-2-3p and miR-130b-3p in GH secreting PitNETs is affected by SSA treatment. Additionally, miR-625-5p can distinguish GH secreting PitNETs from other PitNET types and healthy controls warranting further research on these miRNAs for treatment efficacy.
Identifiants
pubmed: 36158656
doi: 10.3389/fonc.2022.894317
pmc: PMC9500360
doi:
Types de publication
Journal Article
Langues
eng
Pagination
894317Informations de copyright
Copyright © 2022 Niedra, Peculis, Litvina, Megnis, Madrika, Balcere, Romanovs, Steina, Stukens, Breiksa, Nazarovs, Sokolovska, Liutkeviciene, Vilkevicute, Konrade and Rovite.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Diagn Pathol. 2010 Dec 07;5:79
pubmed: 21138567
Medicine (Baltimore). 2021 Apr 9;100(14):e25306
pubmed: 33832102
Genome Biol. 2014;15(12):550
pubmed: 25516281
Molecules. 2019 Apr 17;24(8):
pubmed: 30999630
Oncotarget. 2017 Mar 28;8(13):21719-21732
pubmed: 28423513
Front Endocrinol (Lausanne). 2022 Apr 22;13:748152
pubmed: 35528014
Turk Neurosurg. 2013;23(6):721-7
pubmed: 24310454
J Endocrinol Invest. 2020 Jul;43(7):947-958
pubmed: 31939196
Int J Endocrinol. 2020 Dec 05;2020:3730657
pubmed: 33354213
Int J Gen Med. 2018 Aug 24;11:337-343
pubmed: 30197531
World Neurosurg. 2019 Oct;130:e888-e898
pubmed: 31299308
Biomolecules. 2018 Apr 26;8(2):
pubmed: 29701682
Endocrinol Metab (Seoul). 2020 Jun;35(2):237-242
pubmed: 32615708
Oncol Res. 2013;21(3):129-36
pubmed: 24512727
Front Cell Dev Biol. 2021 Mar 22;9:616306
pubmed: 33829013
Int J Gen Med. 2013;6:31-8
pubmed: 23359786
PLoS One. 2015 May 05;10(5):e0125553
pubmed: 25942502
Front Pharmacol. 2020 Jan 20;10:1500
pubmed: 32038230
Front Genet. 2019 Jul 18;10:626
pubmed: 31379918
Cancers (Basel). 2021 Mar 19;13(6):
pubmed: 33808624
Front Microbiol. 2020 Jun 03;11:1197
pubmed: 32582115
Int J Cancer. 2020 Dec 15;147(12):3523-3538
pubmed: 32856736
J Neurosurg. 2018 Apr;128(4):1051-1057
pubmed: 28452619
Endocrinol Metab Clin North Am. 2020 Sep;49(3):347-355
pubmed: 32741475
Front Endocrinol (Lausanne). 2018 Aug 03;9:402
pubmed: 30123182
Eur Endocrinol. 2018 Sep;14(2):57-61
pubmed: 30349595
Signal Transduct Target Ther. 2016 Jan 28;1:15004
pubmed: 29263891
Genes (Basel). 2018 Jul 04;9(7):
pubmed: 29973528
Am J Physiol Endocrinol Metab. 2012 Sep 15;303(6):E708-19
pubmed: 22811466
Mol Cell Endocrinol. 2014 Jun 5;390(1-2):1-7
pubmed: 24681352
BMC Med Genomics. 2015 Oct 14;8:61
pubmed: 26462558
Sci Rep. 2020 Mar 27;10(1):5644
pubmed: 32221351
J Cell Mol Med. 2014 Mar;18(3):371-90
pubmed: 24533657
J Thorac Oncol. 2012 Jul;7(7):1184-91
pubmed: 22617246
J Clin Endocrinol Metab. 1990 Dec;71(6):1427-33
pubmed: 1977759
Front Genet. 2013 May 24;4:94
pubmed: 23745127
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Front Endocrinol (Lausanne). 2019 Dec 10;10:837
pubmed: 31920960
Cancers (Basel). 2020 Feb 22;12(2):
pubmed: 32098443
Turk J Med Sci. 2021 May 20;51(4):2081-2086
pubmed: 34013701
Endocr J. 2019 Aug 29;66(8):709-722
pubmed: 31061247
J Clin Endocrinol Metab. 2012 Jul;97(7):E1128-38
pubmed: 22564666
Acta Neuropathol. 2017 Oct;134(4):521-535
pubmed: 28821944
Front Bioeng Biotechnol. 2021 Oct 18;9:687915
pubmed: 34733825
BMC Cancer. 2017 Nov 09;17(1):730
pubmed: 29121858
Arch Endocrinol Metab. 2016 Nov-Dec;60(6):554-561
pubmed: 27982201
J Clin Endocrinol Metab. 2008 Apr;93(4):1254-62
pubmed: 18171702
Mol Cell Endocrinol. 2021 Oct 1;536:111350
pubmed: 34098015
Diabetes Metab Syndr Obes. 2020 Jul 27;13:2667-2676
pubmed: 32821139
Cancers (Basel). 2020 Mar 31;12(4):
pubmed: 32244548
Front Endocrinol (Lausanne). 2020 Jun 05;11:331
pubmed: 32582027
QJM. 2017 Jul 1;110(7):411-420
pubmed: 26873451
Oncotarget. 2017 Jul 11;8(28):45874-45887
pubmed: 28501857
J Clin Endocrinol Metab. 2019 May 21;:
pubmed: 31112271